Kornimate/medical-research-clean huggingface dataset:
role of metabolic enzymes in non-melanoma skin cancer

Conditions: Skin Cancer

Summary: the researcher can proved that certain compounds play an important role in the prevention of skin cancer. researcher can use specific compounds, which classified as metabolic enzymes, and lower concentrations and complete absent in skin cancer cells. researcher can biopsies of normal skin and precancerous or cancerous lesions, and can compare the concentrations of these compounds to determine the difference between the two areas. the result can lead to further understanding of skin cancers and pre-cancers. because skin cancers and pre-cancers are so common, any knowledge would be very useful for many people in the future and may be used for development of future treatments or prevention strategies.

biopsy procedure will be done at the beckman laser institute or at the dermatology clinic gottschalk medical plaza, of university of california, irvine. standard procedure of punch biopsy will be done in the areas determined by the physician researchers. the normal skin biopsy will be obtained from an area of skin without any suspicious lesions located on an area of the body. biopsy specimens will be stored frozen at beckman laser institute chemistry-lab for research and will be assigned with subject id number, there will be no personnel health information attach to the skin specimens. there will be no cost to the subject or their insurer for participation in this study, except in the specific scenario of a suspected skin cancer that would undergo biopsy regardless of participation in this study. the time commitment for each subject is approximately 1 hour for each set of biopsies. researchers can test the hypothesis that expression of key metabolic enzymes is reduced and/or lost during skin cancer progression. total ribonucleic acid, a single-stranded biologic molecule involved in gene transcription, regulation, and translation, can be isolated from biopsied skin specimens. quantitative real-time can be performed to determine the expression levels of several key metabolic enzymes. metabolic enzymes regulate several vital signaling pathways in the human body. some examples include hormone and bioactive lipid regulation. aberrant regulation of these signaling pathways can lead to human diseases including cancer. recent evidence has shown that metabolic enzyme call ugt in the genes call udp-glucuronosyltransferases were shown to have significantly reduced expression in breast tumors compared with normal breast tissue from the same patients this observed loss of expression is hypothesized to be causal as these two enzymes are responsible for estrogen metabolism. however, relatively little is known about metabolic enzymes and skin cancer. we have preliminary data that ugt enzyme expression is lost during melanoma progression which allows deregulated lipoxygenase signaling.

Eligibility criteria:
inclusion criteria: * male or female are age18 years and older * have normal skin and a skin lesion of interest * willing to have skin biopsies on those areas exclusion criteria: * male or female are under 18 years of age * pregnant women
the study will evaluate the efficacy of azd5423 in patients with mild asthma challenged with an inhaled allergen

Conditions: Asthma

Summary: the purpose of this study is to evaluate the efficacy of azd5423 in patients with mild asthma challenged with an inhaled allergen.


Eligibility criteria:
inclusion criteria: * 18-60 years of age * pre-bronchodilatory fev1 ≥70% of predicted normal allergic asthmatic with a history of episodic wheeze * positive allergen induced early and late airway bronchoconstriction showing ≥ 20% fall in fev1 for the early and ≥ 15% for the late response * positive skin prick test to common aeroallergens exclusion criteria: * any clinically significant disease or disorder * any clinically relevant abnormal finding at screening examinations * smoker or ex-smoker who has stopped smoking \< 12 months prior to study start * worsening of asthma or respiratory infection within 6 weeks from visit 1 * allergen-specific immunotherapy within 6 months prior to visit 1

Keywords: allergen challenge asthma inhaled selective glucocorticoid receptor agonist (isegra)
psoas compartment block versus fascia iliaca block after total hip arthroplasty

Conditions: Pain

Summary: a psoas compartment block has been used with good results for postoperative pain relief after total hip arthroplasty (tha). however, case reports describing serious complications after the use of this block, have been reported. the fascia iliaca compartment block (ficb) has been shown to be a reliable block for postoperative pain relief for procedures and injuries involving the hip. the investigators have not found any literature that has compared these two blocks. this study will compare the two blocks when used for post-operative pain relief after tha.


Eligibility criteria:
inclusion criteria: * asa class i-iii * patients undergoing tha for osteoarthritis exclusion criteria: * skin infections adjacent to block site * allergy to local analgesics * patient unable to understand visual analogue scale (vas)

Keywords: pain score
pain perception: on relationships between dental anxiety and olfaction

Conditions: Dental Anxiety; Dental Pain; Essential Oil

Summary: the objective of this study is to evaluate the ability of olfaction in obtaining positive emotional and behavioral responses toward dental anxiety and pain in patients undergoing different dental procedures.

all patients who meet inclusion criteria of the study will be given a written consent and enrolled into a randomized double-blinded controlled study (investigator and patients are blinded about the study). patients will be divided into lavender and control groups. patients in lavender group will subjected 2 % lavender vapors. in control group, patients will inhale distal water vapors

Eligibility criteria:
inclusion criteria: 1. adult females over 18 years, 2. attending morning sessions of clinics (9 am) 3. liable for administration of local anesthesia, tooth preparation either for filling procedures or crown preparations, endodontic treatment, teeth extraction, or subgingival scaling exclusion criteria: 1. males 2. females who had allergies, bronchial asthma, common cold, pulmonary diseases, migraine, or taking antidepressants, anxiolytic drugs, opioids, or other medications that affect our results

Keywords: dental anxiety dental pain emotional changes olfaction essential oil lavender
vaccine observation to include all communities for equitable science

Conditions: Vaccine Response Impaired; Vaccine Adverse Reaction

Summary: voices is a longitudinal, prospective, observational study that will enroll up to 10,000 subjects of diverse racial backgrounds being administered an emergency use authorized covid-19 vaccine, for collection and analysis of stool and blood samples. it has recently been shown that the gut microbiome, the collection of microbes that line our gi tract, play a significant role in vaccine immune response and severe complications from covid-19. the identification of biomarkers may aid in predicting response to vaccination and are critical towards improving vaccine-induced immunity. these real-world patient derived biomarkers could be used as interventional targets for the design of innovative adjuvant co-therapies that can boost an effective immune response to the vaccine, enhancing efficacy for a broader population, including those at most risk. subjects who meet the entry criteria will provide two samples each of blood, one prior to and one following vaccine administration. follow-up questionnaires will be sent at 3, 6, 9, and 12 months to determine if participants have contracted covid-19 or have experienced any adverse effects of the vaccine. nasal swab samples will also be collected from participants that have contracted covid-19. the samples will be analyzed to determine the impact of gut microbiome composition and function on the immune system and vaccine efficacy.


Eligibility criteria:
inclusion criteria: * men or women who are ≥ 18 years old and expecting to receive the sars-cov-2 vaccine within the next 30 days. * subjects who are able to provide written informed consent. exclusion criteria: * subjects with known hiv, hepatitis a, hepatitis b, hepatitis c, or sars-cov-2 infection within 4 weeks of vaccination * subjects without the mental capacity to complete either a written or online questionnaire, alone or with assistance, or make sound decisions * women who are pregnant, plan on becoming pregnant, or are nursing.

Keywords: sars-cov-2 covid-19 gut microbiome vaccine
investigating effect of convalescent plasma on covid-19 patients outcome: a clinical trial

Conditions: Coronavirus Infections

Summary: coronavirus disease 2019 (covid-19) was recognized as a pandemic on march 11, 2020 by the world health organization. the virus that causes covid-19 (sars-cov-2) is easily transmitted through person to person and there is still no specific approach against the disease and mortality rate in severe cases is also significant. therefore, finding effective treatment for the mortality of these patients is very important. in this study the investigators aim to determine the effect of convalescent plasma on covid-19 patients outcome through a clinical trial


Eligibility criteria:
inclusion criteria: recipient: 1. covid-19 patients 2. consent to attend the study 3. age 30 to 70 years 4. don't be intubated 5. pao2 / fio2 is above 200 or spo2 is greater than 85%. donator: 1. complete recovery from severe covid-19 disease and hospital discharge 2. consent to donate blood to the infected person 3. age 30 to 60 years 4. has normal cbc test results 5. negative covid-19 rt-pcr test exclusion criteria: recipient: 1. a history of hypersensitivity to blood transfusions or its products 2. history of iga deficiency 3. heart failure or any other factor that prevents the transmission of of 500 ml plasma 4. entering the intubation stage donator: 1. patients infected with blood-borne viral / infectious diseases 2. underlying heart disease, low or high blood pressure, diabetes, epilepsy, and anything that may prohibit blood donation. 3. use of banned drugs for blood donation (eg, ethertinate, acitretin, aliotretinoin, isotretinoin, antiandrogens, nsaids, etc.) 4. use of different drugs 5. other prohibited donations based on blood transfusion standards

Keywords: coronavirus covid-19 sars-cov-2 severe acute respiratory syndrome coronavirus 2
the tilt test-induced response in closed-loop stimulation (tirecs) study

Conditions: Syncope, Vasovagal, Neurally-Mediated

Summary: multicentre, prospective, double blinded, randomized study designed as an intrapatient comparison to evaluate the effects of the biotronik closed-loop stimulation algorithm on prevalence and timing of haemodynamic variations and clinical prodromes induced by head-up tilt test in patients underwent pacemaker implantation for refractory cardioinhibitory vasovagal syncope.

a total of 30 patients with refractory cardioinhibitory vasovagal syncope receiving a biotronik pacemaker with closed-loop stimulation (cls) algorithm will be enrolled in the study. two head-up tilt test (hutt), one during ddd 60/min pacing with cls algorith turned off (cls-off) and the other during ddd-cls pacing (cls-on), will be performed one week apart; patients will be randomly and blindly assigned to group a (n=15, first hutt in cls-on mode) or b (n=15, first hutt in cls-off mode). during hutt heart rate, blood pressure, and the incidence of clinical prodromes and syncope wil be recorded.

Eligibility criteria:
inclusion criteria: * refractory cardioinhibitory vasovagal syncope treated with permanent pacemaker; * pacemaker biotronik with closed-loop stimulation algorithm * ability to perform a head up tilt test * completion of the 18th year of age exclusion criteria: * contraindications to head up tilt test
effect of immersive virtual reality exergames in patients with parkinson's disease

Conditions: Parkinson Disease

Summary: the study aimed to investigate the effect of applying cognitively challenging exergames using fully immersive virtual reality in patients with parkinson's disease.

it has been reported that dual-task training involving both cognitive and physical functions helps improve walking speed during dual-task performance without increasing the fall risk in patients with parkinson's disease (pd). compared with conventional physical therapy, there are studies that dual-task training significantly improved walking speed and stride in pd patients. in addition, a systematic review study has been reported that it helps to improve balance and cognitive function when dual-task training is performed for patients with neurological diseases including parkinson's disease. virtual reality is expected to promote functional recovery in patients with neurological disorders in terms of providing an enriched environment, goal-directed tasks and repetition, and inducing interest and motivation. therefore, the study aimed to investigate the effect of applying cognitively challenging exergames using fully immersive virtual reality in patients with pd.

Eligibility criteria:
inclusion criteria: * clinically diagnosed as idiopathic parkinson's disease * modified hoehn \& yahr stage 2, 2.5, or 3 exclusion criteria: * moderate to severe cognitive dysfunction with mini-mental state examination score \< 19 * severe dyskinesia or severe on-off phenomenon * plan to adjust medication at the time of screening * other brain diseases such as stroke, brain tumor, etc * history of seizure * vestibular disease or paroxysmal vertigo * other comorbidities that make it difficult to participate in this study

Keywords: parkinson's disease virtual reality exergame
oxytocin and pain sensitivity and threshold

Conditions: Pain

Summary: oxytocin is neurohypophysial peptide that acts mainly as a neuromodulator in the brain. in addition,oxytocin have an important roles in sexual reproduction , in particular during and after childbirth. it facilitates birth, maternal bonding, and, breastfeeding. nasal oxytocin has been commonly used to improve breastfeeding in lactating women. a review of safety , side effects and subjective reaction to intranasal oxytocin in human research in 1529 subjects did not review any differences from placebo. the vast majority of basic science studies suggested a large effect of oxytocin in minimizing acute pain.4 few studies have demonstrated an association between plasma levels of oxytocin and pain in humans. no studies have examined the effect of intranasal oxytocin on pain sensitivity and threshold. since addictive properties of oxytocin have not been described, the drug may have important application in the management of acute and chronic pain. the main objective of the current investigation was to evaluate the effect of intranasal oxytocin on pain sensitivity and threshold in human volunteers. we hypothesized that intranasal oxytocin, in human volunteers ,would decrease sensitivity and and increase pain threshold compared to intranasal saline . significance: intranasal oxytocin may become a viable treatment for acute and chronic pain in humans.


Eligibility criteria:
inclusion criteria: * healthy males and females volunteers * english speaking * age \ 35 exclusion criteria: * pregnancy * lactation * allergy to preservatives * mental disease * chronic pain * current use of analgesics * anxiety or depression drop out: volunteer request

Keywords: pain oxytocin
a study of jnj-75229414 for metastatic castration-resistant prostate cancer participants

Conditions: Prostatic Neoplasms

Summary: the purpose of this study is to determine recommended phase 2 dose (rp2d) regimen(s) of jnj-75229414 in part 1 (dose escalation and to determine safety at the rp2d regimen(s) in part 2 (dose expansion).


Eligibility criteria:
inclusion criteria: * histology: metastatic crpc (mcrpc) with histologic confirmation of adenocarcinoma. metastatic crpc with neuroendocrine features or mixed histology is excluded * prior therapy: prior treatment with at least 1 prior novel androgen receptor ar-targeted therapy (that is, abiraterone acetate, apalutamide, enzalutamide, darolutamide), or at least 1 prior chemotherapy (example, docetaxel) * eastern cooperative oncology group (ecog) performance status grade of 0 or 1 * measurable disease by response evaluation criteria in solid tumors (recist) v1.1 or detectable prostate-specific antigen (psa) levels based on local laboratory results * fertile participants must use a condom with spermicide during any sexual contact with a woman of childbearing potential, including pregnant women, from the time of signing the icf until 1 year after receiving a jnj-75229414 infusion. vasectomized participants must agree to use a condom to protect any sexual partner from exposure to semen for 1 year after receiving the last dose of study drug. contraceptive (birth control) use should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies exclusion criteria: * prior grade 4 cytokine release syndrome (crs) or grade 3 or grade 4 neurotoxicity related to any t cell redirection (bispecific cluster of differentiation \[cd 3\]) * prior kallikrein 2 (klk2)-targeted therapy * prior chimeric antigen receptor t cell (car-t) therapy * receiving systemic treatment less than or equal to (\ =) 6 weeks prior signing informed consent are allowed * less than 2 weeks between last administration anti-androgen agents (example, abiraterone or enzalutamide), poly adenosine diphosphate-ribose polymerase (parp) inhibitors (example, olaparib) or radiotherapy, and less than 3 weeks between last administration of cytotoxic chemotherapy (example, docetaxel), radionuclides (example, radium-223, lutetium-177-prostate-specific membrane antigen \[psma\]-617) or an investigational agent, and apheresis
the effect of oral probiotics on glycemic control of women with gestational diabetes mellitus

Conditions: Gestational Diabetes Mellitus

Summary: scientific background: uncontrolled gestational diabetes mellitus (gdm) is associated with severe maternal and neonatal morbidities. treatment of gdm is multidisciplinary and includes lifestyle changes and medications. however, the efficacy of these treatments is limited due to poor motivation, daily painful blood tests and multiple injections. probiotic supplements were shown to modulate the gut microbiome by reducing the adverse metabolic effects associated with pathogenic microbial colonization. promising effects on glycemic control and insulin resistance in non-pregnant diabetic patients were reported. however, the effect of probiotics on glycemic control in gdm has not been elucidated. objectives: to examine the effect of a mixture of probiotic strains given daily on maternal glycemic parameters, and pregnancy outcomes among women with gdm. working hypothesis: oral administration of probiotics will be effective in glucose control of patients with gdm and their neonates without causing significant adverse effects. type of research and methods of data collection: a prospective randomized, double blind, placebo controlled trial. women newly diagnosed with gdm will be recruited and followed in the gdm clinic and maternal-fetal medicine ward (including the research clinic) at emek medical center. they will be divided into a research group, receiving the probiotic formula femina ii and a control group, receiving a placebo (2 capsules/day) until delivery. glycemic control will be evaluated by daily glucose charts. after 2 weeks of diet and probiotic/placebo treatment and thereafter, pharmacotherapy will be started in case of poor glycemic control according to the daily glucose charts. blood tests for glycated molecules will be performed. fetal well-being and growth will be assessed. the primary outcomes are: 1. the rate of women requiring medications for glycemic control 2. mean value of the mean daily glucose charts after 2 weeks of treatment with the study products.


Eligibility criteria:
inclusion criteria: * pregnant women who were diagnosed with gdm from 13 to 32.6 gestational weeks * 18 years old and older * singleton pregnancy exclusion criteria: * women with pre-gestational diabetes mellitus * gdm diagnosed ≥ 33 gestational weeks * women using prophylactic antimicrobial treatment * immunocompromised women * multiple pregnancy * women taking oral probiotic products who refuse to stop the consumption (food-containing probiotics is not considered an exclusion criterion).
multicomponent yoga intervention for major depressive disorder

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to evaluate the efficacy of a multi-component yoga intervention featuring sudarshan kriya yoga (sky) as an adjunctive treatment for patients with major depressive disorders with incomplete response to antidepressants.

according to the world health organization, compared to two hundred health conditions, depression is ranked as the second leading cause of disability worldwide. the annual prevalence of major depressive disorder (mdd) in the united states is estimated at 7% and the lifetime risk approximately 17%. depression is associated with approximately 75% of all deaths by suicide, resulting in immense suffering for families and society at large. 83 billion dollars are spent per year on treatment and lost productivity related to the disorder. current treatments for mdd have remission rates between 35-50%. patients who respond to treatment, but do not experience clinical remission are at markedly increased risk for relapse. approximately 50% of patients treated with two trials of antidepressant interventions do not achieve clinical remission. consequently, novel evidence-based treatment modalities that can further treat this devastating disorder are needed. mind-body interventions constitute a large and diverse group of practices that reduce both stress and inflammation and are increasingly being evaluated in the treatment of mdd the 2007 nhis concluded that 16.6% of u.s. adults, representing 34.1 million americans, used at least one mind-body intervention in the past year. initial studies with different mind-body interventions have been shown to improve outcomes in mdd. a recent meta-analysis gave a grade b for current evidence for the use of yoga as an intervention for mdd. sudarshan kriya yoga (sky) is a advanced yogic breathing intervention that has been reported to relieve symptoms of major depressive disorder and generalized anxiety disorder. in mdd, sky can correct the p300 amplitude, decrease plasma cortisol levels and increase plasma prolactin levels. in a small-scale randomized controlled trial, 45 consenting inpatients meeting criteria for dsm-iv severe, melancholic depression were randomized to receive sky, electroconvulsive therapy (ect) or imipramine treatment for four weeks (janakiramaiah et al. 2000). consequently, the rigorous evaluation of a multicomponent yogic intervention featuring sky as an adjunctive treatment for adults with mdd warrants further study.

Eligibility criteria:
inclusion criteria: * dsm-iv major depressive disorder * able to give informed consent * aged 18-67 * currently in outpatient care for mdd * on a stable antidepressant regimen for at least 2 months * 17-item hamilton depression score \>14 at screening \& baseline visit exclusion criteria: * currently in crisis requiring inpatient treatment * bipolar disorder, psychotic disorder, adhd, substance use disorder * pregnancy, epilepsy * initiating psychotherapy or other yoga/meditation program